Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. The combination of tremelimumab and durvalumab is now a standard treatment option for advanced HCC. Objective: To study immune responses in HCC patients treated with tremelimumab and durvalumab. Design: We treated 28 HCC patients with durvalumab, tremelimumab and locoregional therapies. We performed a high-dimensional multiomics analysis including whole exome sequencing, single-cell RNA seq, CO-Detection by indEXing, flow cytometry and multiplex cytokine/chemokine analysis of patients’ blood and tumour samples and integrated this data to elucidate immune correlatives and response mechanisms. Mice with syngeneic HCC were treated with anti-PD-L1 plus anti-CTLA4 for hepatic lymphocytes, tumour-infiltrating lymphocytes and peripheral blood mononuclear cell analysis. Results: The median overall survival was 19.2 months. Tumour tissue analysis revealed enhanced interferon responses, with stronger effects in responders. Gene set variation analysis indicated enhanced antigen presentation in responders. Spatial analysis revealed that non-responder tumours had higher numbers of Tregs located in neighbourhoods enriched with immune cells and expressed higher levels of ICOS and PD-1. Conversely, non-responder PD1+CD8+T in these Treg-enriched neighbourhoods expressed lower ICOS. Cell-communication analysis demonstrated that Treg-CD8+T interaction was enhanced in non-responder tissue. Peripheral blood analysis showed increased classical monocytes in responders and Tregs in non-responders. Treg-CD8+T interaction was confirmed in preclinical models. Finally, single-patient computational analysis from the all-across analysis was performed on 860 features, which led to the identification of multiomics feature sets including Treg features. Conclusion: Our study provides a blueprint for in-depth analysis of immune correlates in immunotherapy studies and demonstrates the importance of Treg distribution in HCC. Trial registration numbers: NCT02821754 and the EudraCT identifier: 2019-002767-98.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In line with high-throughput technologies, several recent studies have utilized spatial and single-cell multiomics to investigate the immune landscape of liver cancers, including hepatocellular carcinoma and cholangiocarcinoma [337–339].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [339]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Inference and analysis of cell-cell communication using CellChat
Jin, S., Guerrero-Juarez, C. F., Zhang, L., Chang, I., Ramos, R., Kuan, C.-H., Myung, P., Plikus, M. V., & Nie, Q. (2021) · Nature Communications · doi:10.1038/s41467-021-21246-9 · Cited by 8,409
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
TIMER2.0 for analysis of tumor-infiltrating immune cells
Li, T., Fu, J., Zeng, Z., Cohen, D., Li, J., Chen, Q., Li, B., & Liu, X. S. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa407 · Cited by 5,209
Determining cell type abundance and expression from bulk tissues with digital cytometry
Newman, A. M., Steen, C. B., Liu, C. L., Gentles, A. J., Chaudhuri, A. A., Scherer, F., Khodadoust, M. S., Esfahani, M. S., Luca, B. A., Steiner, D., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0114-2 · Cited by 4,478
xCell: digitally portraying the tissue cellular heterogeneity landscape
Aran, D., Hu, Z., & Butte, A. J. (2017) · Genome Biology · doi:10.1186/s13059-017-1349-1 · Cited by 4,397
Becht, E., Giraldo, N. A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., Selves, J., Laurent-Puig, P., Sautès-Fridman, C., Fridman, W. H., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1070-5 · Cited by 3,685
Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Abou-Alfa, G. K., Lau, G., Kudo, M., Chan, S. L., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., De Toni, E. N., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2100070 · Cited by 1,576
Cited by
(2025) · doi:10.1038/s41423-025-01313-7 · Cited by 97
Cheng, X., Peng, T., Chu, T., Yang, Y., Liu, J., Gao, Q., Cao, C., & Wei, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01722-1 · Cited by 82
SPP1 + macrophages cause exhaustion of tumor-specific T cells in liver metastases
Trehan, R., Huang, P., Zhu, X. B., Wang, X., Soliman, M., Strepay, D., Nur, A., Kedei, N., Arhin, M., Ghabra, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59529-0 · Cited by 74
Self-citationLiu, F., Li, X., Zhang, Y., Ge, S., Shi, Z., Liu, Q., & Jiang, S. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03490-9 · Cited by 54
Spatial single-cell omics: new insights into liver diseases
Suo, Y., Thimme, R., & Bengsch, B. (2025) · Gut · doi:10.1136/gutjnl-2024-332105 · Cited by 30
Metadata
- Authors
- Myojin, Y., Babaei, S., Trehan, R., Hoffman, C., Kedei, N., Ruf, B., Benmebarek, M.-R., Bauer, K. C., Huang, P., Ma, C., Monge, C., Xie, C., Hrones, D., Duffy, A. G., Armstrong, P., Kocheise, L., Desmond, F., Buchalter, J., Galligan, M., Cantwell, C., Ryan, R., McCann, J., Bourke, M., Mac Nicholas, R., McDermott, R., Awosika, J., Cam, M., Krebs, R., Budhu, A., Revsine, M., Figg, W. D., Kleiner, D. E., Redd, B., Wood, B. J., Wang, X. W., Korangy, F., Claassen, M., & Greten, T. F.
- Affiliations
- National Institutes of Health (US)
- Universitätsklinikum Tübingen (DE)
- Collaborative Protein Technology Resources, Office of Science and Technology Resources, National Institutes of Health, Bethesda, Maryland, USA
- Gastrointestinal Malignancies Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
- Mater Misericordiae University Hospital (IE)
- University College Dublin (IE)
- St Vincent’s University Hospital, University College Dublin, Dublin, Ireland
- Corresponding author
- Greten, Tim F
- ORCID
- Myojin, Yuta
- Babaei, Sepideh
- Trehan, Rajiv
- Ruf, Benjamin
- Benmebarek, Mohamed-Reda
- Bauer, Kylynda C
- Huang, Patrick
- Ma, Chi
- Xie, Changqing
- Hrones, Donna
- Duffy, Austin G
- Armstrong, Paul
- Kocheise, Lorenz
- Desmond, Fiona
- Buchalter, Jemma
- Galligan, Marie
- Cantwell, Colin
- McDermott, Ray
- Awosika, Joy
- Cam, Maggie
- Budhu, Anuradha
- Revsine, Mahler
- Figg, William D
- Kleiner, David E
- Redd, Bernadette
- Wood, Bradford J
- Wang, Xin Wei
- Korangy, Firouzeh
- Claassen, Manfred
- Greten, Tim F
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2025-02-18
- Volume
- 74
- Issue
- 6
- Pages
- 983-995
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- PMC
- PMC12392412
- OpenAlex
- W4407690978
- Cited by
- 24
- References
- 38
- Citations by year
- 2026: 9 · 2025: 15
- FWCI
- 9.94
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Gut (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Japan Society for the Promotion of Science (NIH-KAITOKU #060042)
- Germany’s Excellence Strategy (EXC 2180 – 390900677)
- the Intramural Research Program of the NIH, NCI (BC 011343, BC 011870)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, tremelimumab, durvalumab, immune checkpoint inhibitors, tumor-infiltrating lymphocytes, regulatory T cells, CD8+ T cells, ICOS, PD-1, interferon response, antigen presentation, classical monocytes, tumor microenvironment, immunotherapy response, multi-omics, intercellular communication, syngeneic mouse model
- MeSH terms
- Multiomics, Aged, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Lymphocytes, Tumor-Infiltrating, T-Lymphocytes, Regulatory, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab. https://app.cochat.ai/papers/10.1136/gutjnl-2024-334026
- The paper
- Myojin, Y., Babaei, S., Trehan, R., Hoffman, C., Kedei, N., Ruf, B., Benmebarek, M.-R., Bauer, K. C., Huang, P., Ma, C., Monge, C., Xie, C., Hrones, D., Duffy, A. G., Armstrong, P., Kocheise, L., Desmond, F., Buchalter, J., Galligan, M., . . . Greten, T. F. (2025). Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab. Gut. https://doi.org/10.1136/gutjnl-2024-334026
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.